PHILADELPHIA, July 08, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the “Class Period”). Investor Deadline: Investors who purchased or acquired Elevance securities during the Class Period may, no later than JULY 11, 2025, seek to be appointed as a lead plaintiff ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline. SO WHAT: If you purchased Elevance common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused Medicaid eligibility reviews during COVID, which resumed in 2023 [3]. Group 3: Allegations of Misrepresentation - Elevance claimed to be closely monitoring cost trends related to the Medicaid redetermination process and asserted that negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - Contrary to these claims, the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Price Impact - On July 17, 2024, Elevance announced an expectation of increased Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - Following the Q3 2024 financial results announcement on October 17, 2024, which revealed a miss in EPS expectations by $1.33 (13.7%) due to elevated medical costs, the stock price fell by $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].

Nonprofits are encouraged to apply now for 2025 funding The Cigna Group Foundation committed $9 million in 2024 to address veteran mental health, distributing $3 million each year through 2026 In first year, 23 grantees were awarded grants to help local veterans feel stable where they live, create positive impact on their mental healthBLOOMFIELD, Conn., July 8, 2025 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), announced today a new round of grants aimed a ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 07, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV) investors of a class action representing investors that bought securities between April 18, 2024 and October 16, 2024, inclusive (the "Class Period"). Elevance investors have until July 11, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. ...

PHILADELPHIA, July 7, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Elevance securities during the Class Period may, no later than JULY 11, 2025, seek to be appointed as a lead plaintiff repre ...

SAN FRANCISCO, July 7, 2025 /PRNewswire/ -- On July 2, 2025, investors in Centene Corp. (NYSE: CNC) saw the price of their shares of this normally low-volatility stock crash 40%, after the company withdrew its guidance, blaming preliminary discussions and data generated by an independent actuary, Wakely.The unusual circumstances and severe investor reaction has prompted national shareholders rights firm Hagens Berman to open an investigation into whether Centene may have violated the securities laws. The fi ...

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Elevance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Elevance between April 18, 2024 and October 16, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 06, 2025 (GLO ...

Core Insights - Centene Corporation experienced a significant stock decline of nearly 40% on July 2 after withdrawing its full-year guidance, attributing the drop to challenges in its Medicaid and Affordable Care Act (ACA) businesses [1][8] - The company's stock closed at $33.31, marking a 38% decrease over the past week [1] Group 1: Stock Performance and Legislative Context - Four U.S. House members sold Centene shares between May 12 and May 30, prior to the company's warning and the passage of the One Big Beautiful Bill Act (OBBBA), which cuts Medicaid funding by $1 trillion over the next decade [3][4] - The OBBBA, passed on July 3, imposes stricter Medicaid work requirements and eligibility checks, potentially removing 10 to 12 million Americans from coverage by 2034 [8] - The timing of congressional stock trades has raised concerns about potential insider trading, given the direct impact of legislation on Centene [9] Group 2: Financial Impact and Market Conditions - Centene disclosed that enrollment and cost trends would reduce earnings by $2.75 per share [8] - The company is facing challenges as healthier enrollees are dropping coverage following the rollback of pandemic-era benefits, resulting in fewer, higher-cost members and squeezing earnings [9] - Critics of the OBBBA warn that it could severely impact low-income families and rural healthcare providers, while supporters argue it will help reduce fraud and abuse [8]